A framework for extremely multiplexed dextramer mapping and prediction of T cell receptor sequences to antigen specificity
T cell receptor (TCR) antigen-specific recognition is important for the adaptive immune system. Nevertheless, constructing a TCR-antigen interplay map has been difficult because of the staggering range of TCRs and antigens. Accordingly, extremely multiplexed dextramer-TCR binding assays have been just lately developed, however the utility of the following giant datasets is restricted by the shortage of sturdy computational strategies for normalization and interpretation.
Right here, we current a computational framework comprising a novel technique, ICON (Integrative COntext-specific Normalization), for figuring out dependable TCR-pMHC (peptide-major histocompatibility complicated) interactions and a neural network-based classifier TCRAI that outperforms different state-of-the-art strategies for TCR-antigen specificity prediction. We additional demonstrated that by combining ICON and TCRAI, we’re capable of uncover novel subgroups of TCRs that bind to a given pMHC through totally different mechanisms. Our framework facilitates the identification and understanding of TCR-antigen-specific interactions for fundamental immunological analysis and medical immune monitoring.
Quantifying persistence within the T-cell signaling community utilizing an optically controllable antigen receptor
T cells discriminate between wholesome and contaminated cells with outstanding sensitivity when mounting an immune response, which is hypothesized to rely on T cells combining stimuli from a number of antigen-presenting cell interactions right into a stronger response. To quantify the capability for T cells to perform this, we now have developed an antigen receptor that’s optically tunable inside cell conjugates, offering management over the length, and depth of intracellular T-cell signaling.
We observe restricted persistence inside the T-cell intracellular community on disruption of receptor enter, with indicators dissipating solely in ~15 min, and straight present sustained proximal receptor signaling is required to keep up gene transcription. T cells thus primarily accumulate the outputs of gene expression slightly than combine discrete intracellular indicators. Engineering optical management in a clinically related chimeric antigen receptor (CAR), we present that this restricted sign persistence will be exploited to extend CAR-T cell activation threefold utilizing pulsatile stimulation. Our outcomes are prone to apply extra typically to the signaling dynamics of different mobile networks.
Tumor rejection properties of gp100 209-specific T cells correlate with T cell receptor binding affinity in direction of the wild sort slightly than anchor-modified antigen
Though there are exceptions and outliers, T cell useful responses typically correlate with the affinity of a TCR for a peptide/MHC complicated. In a single just lately described outlier case, essentially the most promising medical candidate in a sequence of TCRs particular for the gp100209 melanoma antigen certain with the weakest resolution affinity and produced the least quantity of cytokine in vitro. Hypotheses for this outlier conduct included uncommon cytokine expression patterns arising from an atypical TCR binding geometry. Learning this occasion in additional element, we discovered right here that outlier conduct is attributable to not uncommon cytokine patterns or TCR binding, however the usage of a place 2 anchor-modified peptide variant in in vitro experiments as an alternative of the wild sort antigen that’s current in vivo.
Though the anchor-modified variant has been extensively utilized in fundamental and medical immunology as a surrogate for the wild sort peptide, prior work has proven that TCRs can clearly distinguish between the 2. We present that when this differential recognition is accounted for, the useful properties of gp100209-specific TCRs observe with their affinity in direction of the peptide/MHC complicated. Past demonstrating the correlates with T cell operate for a clinically related TCR, our outcomes present necessary concerns for choice of TCRs for immunotherapy and the usage of modified peptides in immunology.
Recombinant Human EBAG9 Protein |
|||
E30P00889A | EnoGene | 50 ug | EUR 295 |
EBAG9 (NM_198120) Human Recombinant Protein |
|||
E45H35833M5 | EnoGene | 20 ug | EUR 785.42 |
EBAG9 (NM_004215) Human Recombinant Protein |
|||
E45H39389M5 | EnoGene | 20 ug | EUR 785.42 |
EBAG9 (NM_004215) Human Recombinant Protein |
|||
PROTO00559 | BosterBio | 20ug | EUR 1249 |
Description: Recombinant protein of human estrogen receptor binding site associated, antigen, 9 (EBAG9), transcript variant 1 |
EBAG9 Protein, Human, Recombinant (His Tag) |
|||
E45H51112E1-100 | EnoGene | 100 ug | EUR 1222.81 |
EBAG9 Protein, Human, Recombinant (His Tag) |
|||
MBS8121611-01mg | MyBiosource | 0.1mg | EUR 450 |
EBAG9 Protein, Human, Recombinant (His Tag) |
|||
MBS8121611-5x01mg | MyBiosource | 5x0.1mg | EUR 1885 |
OPCA03845-1MG - EBAG9 Recombinant Protein (Human) |
|||
OPCA03845-1MG | Aviva Systems Biology | 1mg | EUR 1379 |
OPCA03845-20UG - EBAG9 Recombinant Protein (Human) |
|||
OPCA03845-20UG | Aviva Systems Biology | 20ug | EUR 218 |
OPCA03845-100UG - EBAG9 Recombinant Protein (Human) |
|||
OPCA03845-100UG | Aviva Systems Biology | 100ug | EUR 323 |
Recombinant Human RCAS1/EBAG9 protein (His tag) |
|||
MBS2570902-002mg | MyBiosource | 0.02mg | EUR 135 |
Recombinant Human RCAS1/EBAG9 protein (His tag) |
|||
MBS2570902-01mg | MyBiosource | 0.1mg | EUR 170 |
Recombinant Human RCAS1/EBAG9 protein (His tag) |
|||
MBS2570902-5x01mg | MyBiosource | 5x0.1mg | EUR 765 |
Recombinant Human RCAS1 / EBAG9 protein (His tag) |
|||
PDEH100304-100ug | Elabscience Biotech | 100ug | EUR 118 |
Description: Human |
Recombinant Human RCAS1 / EBAG9 protein (His tag) |
|||
PDEH100304-20ug | Elabscience Biotech | 20ug | EUR 68 |
Description: Human |
Recombinant Rat EBAG9 Protein, His (Fc)-Avi-tagged |
|||
EBAG9-1654R | Creative BioMart | 50ug | EUR 2398.4 |
Description: For long term storage, aliquot and store at -20 to -80 centigrade. Avoid repeated freezing and thawing cycles. |
Recombinant Mouse EBAG9 Protein, His (Fc)-Avi-tagged |
|||
EBAG9-2613M | Creative BioMart | 50ug | EUR 2398.4 |
Description: For long term storage, aliquot and store at -20 to -80 centigrade. Avoid repeated freezing and thawing cycles. |
Recombinant Human RCAS1/ EBAG9 Protein, His-SUMO, E.coli-1mg |
|||
QP5959-ec-1mg | EnQuireBio | 1mg | EUR 1958.4 |
Recombinant Human RCAS1/ EBAG9 Protein, His-SUMO, E.coli-10ug |
|||
QP5959-ec-10ug | EnQuireBio | 10ug | EUR 240 |
Recombinant Human RCAS1/ EBAG9 Protein, His-SUMO, E.coli-50ug |
|||
QP5959-ec-50ug | EnQuireBio | 50ug | EUR 315.6 |
Recombinant Human RCAS1/ EBAG9 Protein, His-SUMO, E.coli-100ug |
|||
QP5959-ec-100ug | EnQuireBio | 100ug | EUR 489.6 |
Recombinant Human RCAS1/ EBAG9 Protein, His-SUMO, E.coli-200ug |
|||
QP5959-ec-200ug | EnQuireBio | 200ug | EUR 760.8 |
Recombinant Human RCAS1/ EBAG9 Protein, His-SUMO, E.coli-500ug |
|||
QP5959-ec-500ug | EnQuireBio | 500ug | EUR 1272 |
EBAG9 protein (His tag) |
|||
80R-1093 | Fitzgerald | 100 ug | EUR 219 |
Description: Purified recombinant Human EBAG9 protein |
Human EBAG9 Protein Lysate |
|||
MBS8410846-002mg | MyBiosource | 0.02mg | EUR 365 |
Human EBAG9 Protein Lysate |
|||
MBS8410846-5x002mg | MyBiosource | 5x0.02mg | EUR 1410 |
OPPA02054-10UG - EBAG9 Protein |
|||
OPPA02054-10UG | Aviva Systems Biology | 10ug | EUR 70 |
Human EBAG9 Protein, His Tag |
|||
E40KMPH4470 | EnoGene | 20ug | EUR 495 |
Human EBAG9 Protein Lysate 20ug |
|||
IHUEBAG9PLLY20UG | Innovative research | each | EUR 213 |
Description: Human EBAG9 Protein Lysate 20ug |
OCOA13214-20UG - EBAG9 Protein Lysate |
|||
OCOA13214-20UG | Aviva Systems Biology | 20ug | EUR 169 |
OCOA20218-20UG - EBAG9 Protein Lysate |
|||
OCOA20218-20UG | Aviva Systems Biology | 20ug | EUR 169 |
OCOA04155-20UG - EBAG9 Protein Lysate |
|||
OCOA04155-20UG | Aviva Systems Biology | 20ug | EUR 169 |
EBAG9 Protein Vector (Rat) (pPM-C-HA) |
|||
PV265296 | ABM | 500 ng | EUR 723.6 |
EBAG9 Protein Vector (Rat) (pPB-C-His) |
|||
PV265294 | ABM | 500 ng | EUR 723.6 |
EBAG9 Protein Vector (Rat) (pPB-N-His) |
|||
PV265295 | ABM | 500 ng | EUR 723.6 |
EBAG9 Protein Vector (Rat) (pPM-C-His) |
|||
PV265297 | ABM | 500 ng | EUR 723.6 |
EBAG9 Protein Vector (Mouse) (pPM-C-HA) |
|||
PV174240 | ABM | 500 ng | EUR 723.6 |
EBAG9 Protein Vector (Human) (pPM-C-HA) |
|||
PV013463 | ABM | 500 ng | EUR 394.8 |
EBAG9 Protein Vector (Human) (pPM-C-HA) |
|||
PV013467 | ABM | 500 ng | EUR 394.8 |
EBAG9 |
|||
CSB-CL007355HU1 | Cusabio | 10 μg plasmid + 200μl Glycerol | Ask for price |
EBAG9 |
|||
CSB-CL007355HU2 | Cusabio | 10 μg plasmid + 200μl Glycerol | Ask for price |
EBAG9 |
|||
pro-343 | ProSpec Tany | 10µg | EUR 60 |
Description: Recombinant Human Estrogen Receptor Binding Site Associated Antigen 9 |
EBAG9 Protein Vector (Mouse) (pPB-C-His) |
|||
PV174238 | ABM | 500 ng | EUR 723.6 |
EBAG9 Protein Vector (Mouse) (pPB-N-His) |
|||
PV174239 | ABM | 500 ng | EUR 723.6 |
EBAG9 Protein Vector (Mouse) (pPM-C-His) |
|||
PV174241 | ABM | 500 ng | EUR 723.6 |
EBAG9 Protein Vector (Human) (pPB-C-His) |
|||
PV013461 | ABM | 500 ng | EUR 394.8 |
EBAG9 Protein Vector (Human) (pPB-N-His) |
|||
PV013462 | ABM | 500 ng | EUR 394.8 |
EBAG9 Protein Vector (Human) (pPM-C-His) |
|||
PV013464 | ABM | 500 ng | EUR 394.8 |
EBAG9 Protein Vector (Human) (pPB-C-His) |
|||
PV013465 | ABM | 500 ng | EUR 394.8 |
EBAG9 Protein Vector (Human) (pPB-N-His) |
|||
PV013466 | ABM | 500 ng | EUR 394.8 |
EBAG9 Protein Vector (Human) (pPM-C-His) |
|||
PV013468 | ABM | 500 ng | EUR 394.8 |
Recombinant Dog Receptor-binding cancer antigen expressed on SiSo cells (EBAG9), partial |
|||
MBS1349708-005mgBaculovirus | MyBiosource | 0.05mg(Baculovirus) | EUR 1115 |
Recombinant Dog Receptor-binding cancer antigen expressed on SiSo cells (EBAG9), partial |
|||
MBS1349708-005mgMammalianCell | MyBiosource | 0.05mg(Mammalian-Cell) | EUR 1335 |
Recombinant Dog Receptor-binding cancer antigen expressed on SiSo cells (EBAG9), partial |
|||
MBS1349708-05mgEColi | MyBiosource | 0.5mg(E-Coli) | EUR 1115 |
Recombinant Dog Receptor-binding cancer antigen expressed on SiSo cells (EBAG9), partial |
|||
MBS1349708-05mgYeast | MyBiosource | 0.5mg(Yeast) | EUR 1335 |
Recombinant Dog Receptor-binding cancer antigen expressed on SiSo cells (EBAG9), partial |
|||
MBS1349708-1mgEColi | MyBiosource | 1mg(E-Coli) | EUR 1635 |
Recombinant Rat Receptor-binding cancer antigen expressed on SiSo cells (Ebag9), partial |
|||
MBS1430359-005mgBaculovirus | MyBiosource | 0.05mg(Baculovirus) | EUR 1115 |
Recombinant Rat Receptor-binding cancer antigen expressed on SiSo cells (Ebag9), partial |
|||
MBS1430359-005mgMammalianCell | MyBiosource | 0.05mg(Mammalian-Cell) | EUR 1335 |
Recombinant Rat Receptor-binding cancer antigen expressed on SiSo cells (Ebag9), partial |
|||
MBS1430359-05mgEColi | MyBiosource | 0.5mg(E-Coli) | EUR 1115 |
Recombinant Rat Receptor-binding cancer antigen expressed on SiSo cells (Ebag9), partial |
|||
MBS1430359-05mgYeast | MyBiosource | 0.5mg(Yeast) | EUR 1335 |
Recombinant Rat Receptor-binding cancer antigen expressed on SiSo cells (Ebag9), partial |
|||
MBS1430359-1mgEColi | MyBiosource | 1mg(E-Coli) | EUR 1635 |
Recombinant Human Receptor-binding cancer antigen expressed on SiSo cells (EBAG9), partial |
|||
CSB-EP007355HU | Cusabio | 1056 mg | Ask for price |
Recombinant Human Receptor-binding cancer antigen expressed on SiSo cells (EBAG9), partial |
|||
CSB-EP007355HU-20ug | Cusabio | 20ug | Ask for price |
Description: 28-213aa |
Recombinant Human Receptor-binding cancer antigen expressed on SiSo cells(EBAG9),partial |
|||
AP70252 | SAB | 1mg | EUR 1978 |
Recombinant Mouse Receptor-binding cancer antigen expressed on SiSo cells (Ebag9), partial |
|||
MBS1320693-005mgBaculovirus | MyBiosource | 0.05mg(Baculovirus) | EUR 1115 |
Recombinant Mouse Receptor-binding cancer antigen expressed on SiSo cells (Ebag9), partial |
|||
MBS1320693-005mgMammalianCell | MyBiosource | 0.05mg(Mammalian-Cell) | EUR 1335 |
Recombinant Mouse Receptor-binding cancer antigen expressed on SiSo cells (Ebag9), partial |
|||
MBS1320693-05mgEColi | MyBiosource | 0.5mg(E-Coli) | EUR 1115 |
Recombinant Mouse Receptor-binding cancer antigen expressed on SiSo cells (Ebag9), partial |
|||
MBS1320693-05mgYeast | MyBiosource | 0.5mg(Yeast) | EUR 1335 |
Recombinant Mouse Receptor-binding cancer antigen expressed on SiSo cells (Ebag9), partial |
|||
MBS1320693-1mgEColi | MyBiosource | 1mg(E-Coli) | EUR 1635 |
Monoclonal EBAG9 Antibody (monoclonal) (M04), Clone: 4A10 |
|||
AMM03477G | Leading Biology | 0.1mg | EUR 580.8 |
Description: A Monoclonal antibody against Human EBAG9 (monoclonal) (M04). The antibodies are raised in mouse and are from clone 4A10. This antibody is applicable in WB, E |
RCAS1/Estrogen Receptor Binding Site Associated, Antigen 9 Recombinant Rabbit Monoclonal Antibody [Clone EBAG9/7033R] |
|||
MBS4382356-002mgWithBSAAzideat02mgmL | MyBiosource | 0.02mg(WithBSA&Azideat0.2mg/mL) | EUR 230 |
RCAS1/Estrogen Receptor Binding Site Associated, Antigen 9 Recombinant Rabbit Monoclonal Antibody [Clone EBAG9/7033R] |
|||
MBS4382356-01mgWithBSAAzideat02mgmL | MyBiosource | 0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 405 |
RCAS1/Estrogen Receptor Binding Site Associated, Antigen 9 Recombinant Rabbit Monoclonal Antibody [Clone EBAG9/7033R] |
|||
MBS4382356-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 405 |
RCAS1/Estrogen Receptor Binding Site Associated, Antigen 9 Recombinant Rabbit Monoclonal Antibody [Clone EBAG9/7033R] |
|||
MBS4382356-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 1725 |
RCAS1/Estrogen Receptor Binding Site Associated, Antigen 9 Recombinant Rabbit Monoclonal Antibody [Clone EBAG9/7033R] |
|||
MBS4382356-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 1725 |
EBAG9 Peptide |
|||
45-515P | ProSci | 0.1 mg | EUR 405.6 |
Description: EBAG9 / RCAS1 Peptide |
EBAG9 antibody |
|||
38323 | SAB | 100ul | EUR 439 |
EBAG9 antibody |
|||
38323-100ul | SAB | 100ul | EUR 302.4 |
EBAG9 antibody |
|||
70R-16981 | Fitzgerald | 50 ul | EUR 289 |
Description: Rabbit polyclonal EBAG9 antibody |
EBAG9 antibody |
|||
70R-9916 | Fitzgerald | 50 ug | EUR 467 |
Description: Affinity purified rabbit polyclonal EBAG9 antibody |
EBAG9 Antibody |
|||
ABD6703 | Lifescience Market | 100 ug | EUR 525.6 |
EBAG9 Antibody |
|||
1-CSB-PA007355GA01HU | Cusabio |
|
|
Description: A polyclonal antibody against EBAG9. Recognizes EBAG9 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC |
EBAG9 Antibody |
|||
CSB-PA007355ZA01HU-02mg | Cusabio | 0.2mg | Ask for price |
Description: Recombinant Homo sapiens EBAG9 protein |
EBAG9 Antibody |
|||
CSB-PA007355ZA01HU-10mg | Cusabio | 10mg | Ask for price |
Description: Recombinant Homo sapiens EBAG9 protein |
EBAG9 Antibody |
|||
DF6703 | Affbiotech | 200ul | EUR 420 |
EBAG9 Antibody |
|||
DF6703-100ul | Affinity Biosciences | 100ul | EUR 168 |
Description: WB,IHC,IF/ICC,ELISA(peptide) |
EBAG9 Antibody |
|||
DF6703-200ul | Affinity Biosciences | 200ul | EUR 210 |
Description: WB,IHC,IF/ICC,ELISA(peptide) |
EBAG9 Antibody |
|||
GWB-MV765I | GenWay Biotech | 50ug | Ask for price |
EBAG9 Antibody |
|||
E300798 | EnoGene | 100ug/200ul | EUR 275 |
Description: Available in various conjugation types. |
EBAG9 Antibody |
|||
E300799 | EnoGene | 100ug/200ul | EUR 275 |
Description: Available in various conjugation types. |
EBAG9 Antibody |
|||
E91935 | EnoGene | 100μg | EUR 255 |
Description: Available in various conjugation types. |
EBAG9 Antibody |
|||
K40051M04H07C-100ug | Absea Biotechnology | 100 ug | EUR 360 |
Description: Monoclonal Antibody |
EBAG9 Antibody |
|||
K40051M04H07C-1mg | Absea Biotechnology | 1 mg | EUR 1800 |
Description: Monoclonal Antibody |
EBAG9 Antibody |
|||
K40051M04H07C-50ug | Absea Biotechnology | 50 ug | EUR 252 |
Description: Monoclonal Antibody |
EBAG9 Antibody |
|||
K40051M10A09C-100ug | Absea Biotechnology | 100 ug | EUR 320 |
Description: Monoclonal Antibody |
EBAG9 Antibody |
|||
K40051M10A09C-1mg | Absea Biotechnology | 1 mg | EUR 1600 |
Description: Monoclonal Antibody |
EBAG9 Antibody |
|||
K40051M10A09C-50ug | Absea Biotechnology | 50 ug | EUR 224 |
Description: Monoclonal Antibody |
EBAG9 Antibody |
|||
K40051M14G10C-100ug | Absea Biotechnology | 100 ug | EUR 280 |
Description: Monoclonal Antibody |
EBAG9 Antibody |
|||
K40051M14G10C-1mg | Absea Biotechnology | 1 mg | EUR 1400 |
Description: Monoclonal Antibody |
EBAG9 Antibody |
|||
K40051M14G10C-50ug | Absea Biotechnology | 50 ug | EUR 196 |
Description: Monoclonal Antibody |
EBAG9 Antibody |
|||
MBS2523105-006mL | MyBiosource | 0.06mL | EUR 190 |
EBAG9 Antibody |
|||
MBS2523105-012mL | MyBiosource | 0.12mL | EUR 265 |
EBAG9 Antibody |
|||
MBS2523105-02mL | MyBiosource | 0.2mL | EUR 415 |
EBAG9 Antibody |
|||
MBS2523105-5x02mL | MyBiosource | 5x0.2mL | EUR 1835 |
EBAG9 Antibody |
|||
MBS9607359-01mL | MyBiosource | 0.1mL | EUR 260 |
EBAG9 Antibody |
|||
MBS9607359-02mL | MyBiosource | 0.2mL | EUR 305 |
EBAG9 Antibody |
|||
MBS9607359-5x02mL | MyBiosource | 5x0.2mL | EUR 1220 |
EBAG9 Antibody |
|||
MBS8505315-01mg | MyBiosource | 0.1mg | EUR 325 |
EBAG9 Antibody |
|||
MBS8505315-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
EBAG9 Antibody |
|||
MBS8505315-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
EBAG9 Antibody |
|||
MBS8505315-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
EBAG9 Antibody |
|||
MBS8505315-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
EBAG9 Antibody |
|||
MBS854258-01mg | MyBiosource | 0.1mg | EUR 345 |
EBAG9 Antibody |
|||
MBS854258-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
EBAG9 Antibody |
|||
MBS854258-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
EBAG9 Antibody |
|||
MBS854258-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
EBAG9 Antibody |
|||
MBS854258-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
EBAG9 Antibody |
|||
MBS854957-01mg | MyBiosource | 0.1mg | EUR 345 |
EBAG9 Antibody |
|||
MBS854957-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
EBAG9 Antibody |
|||
MBS854957-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
EBAG9 Antibody |
|||
MBS854957-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
EBAG9 Antibody |
|||
MBS854957-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
EBAG9 antibody |
|||
MBS9405267-005mL | MyBiosource | 0.05mL | EUR 300 |
EBAG9 antibody |
|||
MBS9405267-01mL | MyBiosource | 0.1mL | EUR 390 |
EBAG9 antibody |
|||
MBS9405267-5x01mL | MyBiosource | 5x0.1mL | EUR 1610 |
Active Recombinant Human ICAM1 Protein (28-480aa), C-hIgG-His-tagged |
|||
ICAM1-14H | Creative BioMart | 5ug | EUR 158.4 |
Description: Can be stored at +2 to +8 centigrade for 1 week. For long term storage, aliquot and store at -20 to -80 centigrade. Avoid repeated freezing and thawing cycles. |
Rat EBAG9 siRNA |
|||
20-abx914879 | Abbexa |
|
|
EBAG9 siRNA (Rat) |
|||
MBS8206041-15nmol | MyBiosource | 15nmol | EUR 405 |
EBAG9 siRNA (Rat) |
|||
MBS8206041-30nmol | MyBiosource | 30nmol | EUR 565 |
EBAG9 siRNA (Rat) |
|||
MBS8206041-5x30nmol | MyBiosource | 5x30nmol | EUR 2450 |
EBAG9 Rabbit pAb |
|||
A1935 | Abclonal | 50μL | EUR 173.58 |
EBAG9 Rabbit pAb |
|||
A1935-100ul | Abclonal | 100 ul | EUR 369.6 |
EBAG9 Rabbit pAb |
|||
A1935-200ul | Abclonal | 200 ul | EUR 550.8 |
EBAG9 Rabbit pAb |
|||
A1935-20ul | Abclonal | 20 ul | EUR 219.6 |
EBAG9 Rabbit pAb |
|||
A1935-50ul | Abclonal | 50 ul | EUR 267.6 |
EBAG9 Rabbit pAb |
|||
A8385 | Abclonal | 200μL | EUR 173.58 |
EBAG9 Rabbit pAb |
|||
A8385-200ul | Abclonal | 200 ul | EUR 550.8 |
EBAG9 Rabbit pAb |
|||
A8385-20ul | Abclonal | 20 ul | Ask for price |
EBAG9 cDNA Clone |
|||
MBS1273084-001mgPlasmid02mLGlycerolStock | MyBiosource | 0.01mgPlasmid+0.2mLGlycerol-Stock | EUR 200 |
EBAG9 cDNA Clone |
|||
MBS1273084-5x001mgPlasmid5x02mLGlycerolStock | MyBiosource | 5x0.01mgPlasmid+5x0.2mLGlycerol-Stock | EUR 855 |
EBAG9 cDNA Clone |
|||
MBS1269322-001mgPlasmid02mLGlycerolStock | MyBiosource | 0.01mgPlasmid+0.2mLGlycerol-Stock | EUR 200 |
EBAG9 cDNA Clone |
|||
MBS1269322-5x001mgPlasmid5x02mLGlycerolStock | MyBiosource | 5x0.01mgPlasmid+5x0.2mLGlycerol-Stock | EUR 855 |
EBAG9 Rabbit pAb |
|||
E2501935 | EnoGene | 100ul | EUR 225 |
Description: Available in various conjugation types. |
EBAG9 Rabbit pAb |
|||
E45R24477N | EnoGene | 50 ul | EUR 297.75 |
EBAG9 Rabbit pAb |
|||
MBS8544680-01mL | MyBiosource | 0.1mL | EUR 305 |
EBAG9 Rabbit pAb |
|||
MBS8544680-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
EBAG9 Rabbit pAb |
|||
MBS8544680-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
EBAG9 Rabbit pAb |
|||
MBS8544680-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
EBAG9 Rabbit pAb |
|||
MBS8544680-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
Mouse EBAG9 siRNA |
|||
20-abx914880 | Abbexa |
|
|
Human EBAG9 siRNA |
|||
20-abx901624 | Abbexa |
|
|
EBAG9 siRNA (Mouse) |
|||
MBS8232252-15nmol | MyBiosource | 15nmol | EUR 405 |
EBAG9 siRNA (Mouse) |
|||
MBS8232252-30nmol | MyBiosource | 30nmol | EUR 565 |
EBAG9 siRNA (Mouse) |
|||
MBS8232252-5x30nmol | MyBiosource | 5x30nmol | EUR 2450 |
EBAG9 siRNA (Human) |
|||
MBS8241103-15nmol | MyBiosource | 15nmol | EUR 405 |
EBAG9 siRNA (Human) |
|||
MBS8241103-30nmol | MyBiosource | 30nmol | EUR 565 |
EBAG9 siRNA (Human) |
|||
MBS8241103-5x30nmol | MyBiosource | 5x30nmol | EUR 2450 |
Human EBAG9 Antibody |
|||
32605-05111 | AssayPro | 150 ug | EUR 215 |
EBAG9 cloning plasmid |
|||
CSB-CL007355HU1-10ug | Cusabio | 10ug | EUR 279.6 |
Description: A cloning plasmid for the EBAG9 gene. |
EBAG9 cloning plasmid |
|||
CSB-CL007355HU2-10ug | Cusabio | 10ug | EUR 279.6 |
Description: A cloning plasmid for the EBAG9 gene. |
Proliferating cell nuclear antigen straight interacts with androgen receptor and enhances androgen receptor‑mediated signaling
Androgen receptor (AR) and/or its constitutively lively splicing variants (AR‑Vs), reminiscent of AR‑V7 and ARv567es, is required for prostate most cancers cell development and survival, and most cancers development. Proliferating cell nuclear antigen (PCNA) is preferentially overexpressed in all cancers and executes its capabilities by way of interplay with quite a few accomplice proteins. The goal of the current research was to research the potential position of PCNA within the regulation of AR exercise.
An equivalent consensus sequence of the PCNA‑interacting protein‑field (PIP‑field) was recognized on the N‑terminus of human, mouse and rat AR proteins. It was discovered that PCNA complexes with the total‑size AR (AR‑FL) and AR‑V7, which will be attenuated by the small molecule PIP‑field inhibitor, T2AA. PCNA additionally complexes with ARv567es and recombinant AR protein. The PCNA inhibitors, PCNA‑I1S and T2AA, inhibited AR transcriptional exercise and the expression of AR goal genes in LNCaP‑AI and 22Rv1 cells, however not in AR‑detrimental PC‑three cells. The knockdown of PCNA expression lowered dihydrotestosterone‑stimulated AR transcriptional exercise and abolished the inhibitory impact of PCNA‑I1S on AR exercise. The PCNA inhibitor, PCNA‑I1, exerted additive development inhibitory results with androgen deprivation and enzalutamide in cells expressing AR‑FL or AR‑FL/AR‑V7, however not in AR‑detrimental PC‑three cells.
Lastly, R9‑AR‑PIP, a small peptide mimicking AR PIP‑field, was discovered to bind to GFP‑PCNA at Okd of two.73 µM and inhibit the expression of AR goal genes, AR transcriptional exercise and the expansion of AR‑expressing cells. On the entire, these information strongly recommend that AR is a PCNA accomplice protein and interacts with PCNA through the PIP‑field and that focusing on the PCNA‑AR interplay might characterize an progressive and selective therapeutic technique towards prostate most cancers, notably castration‑resistant prostate cancers overexpressing constitutively lively AR‑Vs.
Novel high-affinity EGFRvIII-specific chimeric antigen receptor T cells successfully remove human glioblastoma
Targets: The rising success of Chimeric Antigen Receptor (CAR) T cell remedy in haematological malignancies is reinvigorating its software in lots of different most cancers varieties and with renewed concentrate on its software to strong tumors. We current a novel CAR towards glioblastoma, an aggressive, malignant glioma, with a dismal survival charge for which therapy choices have remained unchanged for over a decade.
Strategies: We use the human Retained Show (ReD) antibody platform (Myrio Therapeutics) to establish a novel single-chain variable fragment (scFv) that recognises epidermal development issue receptor mutant variant III (EGFRvIII), a typical and tumor-specific mutation present in glioblastoma. We use each in vitro useful assays and an in vivo orthotopic xenograft mannequin of glioblastoma to look at the operate of our novel CAR, known as GCT02, focused utilizing murine CAR T cells.
Outcomes: Our EGFRvIII-specific scFv was discovered to be of a lot increased affinity than reported comparators reverse-engineered from monoclonal antibodies. Regardless of the upper affinity, GCT02 CAR T cells kill equivalently however secrete decrease quantities of cytokine. As well as, GCT02-CAR T cells additionally mediate fast and full tumor elimination in vivo.
Conclusion: We current a novel EGFRvIII-specific CAR, with efficient antitumor capabilities each in in vitro and in a xenograft mannequin of human glioblastoma.
P1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV739461 | ABM | 1.0 ug DNA | Ask for price |
NP Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV814303 | ABM | 1.0 ug DNA | EUR 540 |
HGF Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV701983 | ABM | 1.0 ug DNA | EUR 540 |
C8A Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV702505 | ABM | 1.0 ug DNA | EUR 540 |
SLN Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV702973 | ABM | 1.0 ug DNA | EUR 540 |
CRP Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV703483 | ABM | 1.0 ug DNA | EUR 540 |
NPL Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV703699 | ABM | 1.0 ug DNA | EUR 540 |
LY9 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV703819 | ABM | 1.0 ug DNA | EUR 540 |
FGA Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV704107 | ABM | 1.0 ug DNA | EUR 540 |
NNT Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV704257 | ABM | 1.0 ug DNA | EUR 540 |
DUT Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV705463 | ABM | 1.0 ug DNA | EUR 540 |
NPL Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV705589 | ABM | 1.0 ug DNA | EUR 540 |
BMF Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV705643 | ABM | 1.0 ug DNA | EUR 540 |
FTO Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV706003 | ABM | 1.0 ug DNA | EUR 540 |
MIP Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV706507 | ABM | 1.0 ug DNA | EUR 540 |
AEN Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV707161 | ABM | 1.0 ug DNA | EUR 379.2 |
AEN Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV707167 | ABM | 1.0 ug DNA | EUR 379.2 |
AGK Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV707191 | ABM | 1.0 ug DNA | EUR 379.2 |
ALB Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV707275 | ABM | 1.0 ug DNA | EUR 379.2 |
ANG Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV707329 | ABM | 1.0 ug DNA | EUR 379.2 |
ATM Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV707659 | ABM | 1.0 ug DNA | EUR 379.2 |
BID Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV707851 | ABM | 1.0 ug DNA | EUR 379.2 |
BMF Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV707875 | ABM | 1.0 ug DNA | EUR 379.2 |
BMF Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV707881 | ABM | 1.0 ug DNA | EUR 379.2 |
CA8 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV708259 | ABM | 1.0 ug DNA | EUR 379.2 |
CA8 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV708265 | ABM | 1.0 ug DNA | EUR 379.2 |
CBS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV708343 | ABM | 1.0 ug DNA | EUR 379.2 |
CBS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV708349 | ABM | 1.0 ug DNA | EUR 379.2 |
CGA Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV708673 | ABM | 1.0 ug DNA | EUR 379.2 |
CKB Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV708757 | ABM | 1.0 ug DNA | EUR 379.2 |
CRK Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV708991 | ABM | 1.0 ug DNA | EUR 379.2 |
CRP Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV708997 | ABM | 1.0 ug DNA | EUR 379.2 |
CRP Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV709003 | ABM | 1.0 ug DNA | EUR 379.2 |
DTL Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV709471 | ABM | 1.0 ug DNA | EUR 379.2 |
OAT Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV712987 | ABM | 1.0 ug DNA | EUR 379.2 |
OS9 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV713023 | ABM | 1.0 ug DNA | EUR 379.2 |
PIP Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV713473 | ABM | 1.0 ug DNA | EUR 379.2 |
PTS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV713989 | ABM | 1.0 ug DNA | EUR 379.2 |
RGR Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV714307 | ABM | 1.0 ug DNA | EUR 379.2 |
TTK Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV716389 | ABM | 1.0 ug DNA | EUR 379.2 |
UBB Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV716533 | ABM | 1.0 ug DNA | EUR 379.2 |
WAC Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV716731 | ABM | 1.0 ug DNA | EUR 379.2 |
AFA Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV718317 | ABM | 1.0 ug DNA | Ask for price |
AIC Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV718395 | ABM | 1.0 ug DNA | Ask for price |
Sp2 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV715321 | ABM | 1.0 ug DNA | EUR 379.2 |
Sp2 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV715327 | ABM | 1.0 ug DNA | EUR 379.2 |
Syk Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV715609 | ABM | 1.0 ug DNA | EUR 379.2 |
TK1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV715879 | ABM | 1.0 ug DNA | EUR 379.2 |
LY9 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV705295 | ABM | 1.0 ug DNA | EUR 540 |
MLS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV733635 | ABM | 1.0 ug DNA | Ask for price |
MOK Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV733689 | ABM | 1.0 ug DNA | Ask for price |
MPE Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV733743 | ABM | 1.0 ug DNA | Ask for price |
MSD Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV734289 | ABM | 1.0 ug DNA | Ask for price |
NSX Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV736497 | ABM | 1.0 ug DNA | Ask for price |
NT3 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV736503 | ABM | 1.0 ug DNA | Ask for price |
OAP Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV736659 | ABM | 1.0 ug DNA | Ask for price |
OED Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV736707 | ABM | 1.0 ug DNA | Ask for price |
TYS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV754917 | ABM | 1.0 ug DNA | Ask for price |
VCF Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV755577 | ABM | 1.0 ug DNA | Ask for price |
VDI Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV755613 | ABM | 1.0 ug DNA | Ask for price |
WSN Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV755991 | ABM | 1.0 ug DNA | Ask for price |
WT2 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV755997 | ABM | 1.0 ug DNA | Ask for price |
WTS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV756003 | ABM | 1.0 ug DNA | Ask for price |
WWS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV756021 | ABM | 1.0 ug DNA | Ask for price |
XCE Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV756045 | ABM | 1.0 ug DNA | Ask for price |
XGR Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV756051 | ABM | 1.0 ug DNA | Ask for price |
XIC Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV756063 | ABM | 1.0 ug DNA | Ask for price |
FTX Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV761757 | ABM | 1.0 ug DNA | EUR 1104 |
CPP Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV759285 | ABM | 1.0 ug DNA | EUR 2148 |
CPQ Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV759291 | ABM | 1.0 ug DNA | EUR 686.4 |
JBS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV730197 | ABM | 1.0 ug DNA | Ask for price |
JPD Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV730203 | ABM | 1.0 ug DNA | Ask for price |
KFM Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV730353 | ABM | 1.0 ug DNA | Ask for price |
KMS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV730473 | ABM | 1.0 ug DNA | Ask for price |
KSS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV730749 | ABM | 1.0 ug DNA | Ask for price |
KWE Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV730755 | ABM | 1.0 ug DNA | Ask for price |
LCO Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV730887 | ABM | 1.0 ug DNA | Ask for price |
MAA Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV732369 | ABM | 1.0 ug DNA | Ask for price |
MCO Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV732645 | ABM | 1.0 ug DNA | Ask for price |
MEB Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV732675 | ABM | 1.0 ug DNA | Ask for price |
mF4 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV732747 | ABM | 1.0 ug DNA | Ask for price |
DM1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV723183 | ABM | 1.0 ug DNA | Ask for price |
DWS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV723519 | ABM | 1.0 ug DNA | Ask for price |
EBM Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV723687 | ABM | 1.0 ug DNA | Ask for price |
EGI Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV723933 | ABM | 1.0 ug DNA | Ask for price |
F7R Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV724761 | ABM | 1.0 ug DNA | Ask for price |
FND Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV725475 | ABM | 1.0 ug DNA | Ask for price |
EVL Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV709843 | ABM | 1.0 ug DNA | EUR 379.2 |
FTL Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV710251 | ABM | 1.0 ug DNA | EUR 379.2 |
FTL Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV710257 | ABM | 1.0 ug DNA | EUR 379.2 |